Nve Corp /New/ (NVEC) Stock Price & Analysis
Nve Corp /New/ (NVEC) rose 1.87% to USD 100.4 as of September 8, 2026 at 10:18 UTC, according to Nexqual real-time market data.
NVEC last closed at USD 100.4; the session ranged USD 99.3–101.45 on volume of 113,075 shares. Market capitalization is —, with a 52-week range of USD 57.21–135 (NCM). Source: Nexqual, September 8, 2026 at 10:18 UTC.
Key Statistics (as of September 8, 2026 at 10:18 UTC)
| Price | USD 100.4 |
|---|---|
| Change | ▲ 1.87% (up) |
| Previous Close | USD 100.4 |
| Open | USD 100.4 |
| Day Range | USD 99.3 – 101.45 |
| 52-Week Range | USD 57.21 – 135 |
| Volume | 113,075 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (NVEC)
Nexqual's technical model rates NVEC "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 10:18 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 48.02 (neutral) |
| vs SMA50 | Below (USD 106.34) |
| MACD | -3.38 (negative) |
From Nve Corp /New/'s Latest SEC 10-K Filing (filed 2026-05-06)
Key Strengths & Strategy (as disclosed to the SEC)
- We protect our proprietary technology and intellectual property by seeking patents, trademarks, and copyrights, and by maintaining trade secrets by entering into confidentiality agreements with employees, suppliers, customers, and prospective customers depending on the circumstances.
- We face various cybersecurity threats, including threats to our information technology infrastructure and attempts to gain access to our proprietary or classified information, and denial-of-service and distributed denial-of-service attacks.
- Also, our confidentiality agreements may not provide meaningful protection of our proprietary information.
- Our inability to maintain our proprietary rights could have a material adverse effect on our business, financial condition, and results of operations. 11 Table of Contents Risks Related to Our Industry   We face an uncertain economic environment in the industries we serve, which could adversely affect our business.
Partnerships
- We have agreements with certain customers, including a Supplier Partnering Agreement, as amended, with Abbott Laboratories, which expires December 31, 2027.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SLSN | Solesence, Inc. | USD 0.85 | ▼ 6.7% |
| VECO | Veeco Instruments Inc. | USD 44.67 | ▲ 3.84% |
| ALTI | AlTi Global, Inc. | USD 3 | ▼ 22.88% |
| NGEN | NervGen Pharma Corp. | USD 2.33 | ▲ 0% |
| ACCL | Acco Group Holdings Limited | USD 2.74 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 10:18 UTC. This page is informational and not investment advice.